Lyra Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
480 Arsenal Way, Watertown, Massachusett...Phone Number
(617) 420-8858Website
www.lyratherapeutics.comRevenue
<$5 MillionStock Symbol
LYRAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Lyra Therapeutics
Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra Therapeutics has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioabsorbable nasal implants designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.Explore more
Lyra Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lyra Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Lyra Therapeutics launches new products
Lyra Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Lyra Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Lyra Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Lyra Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Lyra Therapeutics
Funding: Get notified immidiatlly once Lyra Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Lyra Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Lyra Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Lyra Therapeutics
Compare insights from companies similar to Lyra Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lyra Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lyra Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lyra Therapeutics.
Lyra Therapeutics financials insights
Gather financial insights about Lyra Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series B
$13.1M
2010
Debt
$2M
Unspecified
$10M
2011
Debt
$3M
2012
Debt
$3M
2013
Debt
$4M
2015
Private Equity
$16M
Series A
$16M
2020
Series C
$30M
Lyra Therapeutics Tech Stack
A closer look at the technologies used by Lyra Therapeutics
Most Recent Scoops
Person-Based
Person-Based
Project
Capacity Planning, Leasing
Person-Based
Person-Based
Lyra Therapeutics News & Media
Triveni Bio raises $92m to take on I&I disorders - BioProcess International
Triveni Bio, emerging from Amagma Therapeutics and Modify Therapeutics, with $92 million, to treat inflammation and immunity (I&I) disorders.Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that it has issued an equity-based award pursuant to its 2022 Inducement Award Plan to its Senior Vice President of Regulatory Affairs, Allison Nance, upon the commencement of her employment. The inducement grant was approved by the CLyra Therapeutics to Present at Jefferies Healthcare Conference
WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023, at 10:30 a.m. ET.Lyra Therapeutics Announces Closing of $50.0 Million Private Placement
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the closing of its previously announced private placement of common stock, pre-funded warrants to purchase common stock and purchase warrants to purchase common stock, resulting in gross proceeds of approximately $50.0 million. The pr
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lyra Therapeutics
Sign Up For FreeTo access detailed company insights
Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra... Read More
